Search results
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoAstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically...
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks via Yahoo Finance· 1 month agoAstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra...
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...
Pennsylvania woman stunned to be charged $50K for asthma medication. No one can explain it
USA TODAY via Yahoo News· 2 years agoYORK, Pa. — Jessica Eckard has always had asthma problems. Her father died of tuberculosis when she...
AstraZeneca drug fails one main goal in study of chronic immune disease
Reuters via Yahoo News· 2 years agoThe condition, eosinophilic esophagitis, is characterised by inflammation and damage to the...
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 8 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
Zacks via Yahoo Finance· 8 months agoData from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut...
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
Zacks via Yahoo Finance· 2 years agoThis week, Novartis NVS and Merck MRK announced their third-quarter earnings. The FDA approved J&J’s...
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
Zacks via Yahoo Finance· 1 month agoThis week, J&J JNJ proposed to buy medical device company Shockwave Medical SWAV for approximately...
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 2 weeks agoAstraZeneca’s AZN first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat...